Evidence map›Paper›PMID 40643201›Full record

ArticleCancer biology & medicine2025

Comprehensive strategies for management of postoperative hyper-progression recurrence (HPR) of hepatocellular carcinoma: a 12-year large sample multi-center study.

Lunan Qi, Jingxuan Xu, Yuanyuan Chen, Zhan Lu, Min Zhou, Yingwu Huang, Yongchi Ling, Hai Huang, Yuchong Peng, Tao Peng and 2 more

Abstract readMulticenter Study
In one paragraph

Article in Cancer biology & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lunan Qi *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.ORCID 0000-0003-0254-6982
Jingxuan Xu *Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Yuanyuan ChenKey Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning 530021, China.
Zhan LuDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Min ZhouKey Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education, Nanning 530021, China.
Yingwu HuangDepartment of Hepatobiliary Surgery, Chongzuo People's Hospital, Chongzuo 532200, China.
Yongchi LingDepartment of Surgery, Fusui County People's Hospital of Guangxi, Fusui 543200, China.
Hai HuangDepartment of Hepatobiliary Surgery, Wuming Hospital of Guangxi Medical University, Wuming 530100, China.
Yuchong PengDepartment of General Surgery, Chongqing Hospital of Traditional Chinese Medicine, Chongqing 400021, China.
Tao PengGuangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research Center, Nanning 530021, China.
Bangde XiangDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Liang MaDepartment of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning 530021, China.ORCID 0000-0001-8106-373X

Funding

Guangxi Nature Sciences 2018GXNSFAA138028National Natural Science Foundation of China 81972306National Natural Science Foundation of China NSFC 82273405
6 · The paper itself

Abstract

objectiveHyper-progression recurrence (HPR) after hepatectomy is a specific recurrence pattern associated with extremely poor prognosis in patients with hepatocellular carcinoma (HCC). This study was aimed at investigating the probable risk factors and establishing comprehensive models for formulating clinical strategies.

methodsOverall, 16,158 patients with HCC from 8 hospitals were screened, among whom 3,125 patients who underwent R0 resection were included, and divided into development (

resultsAmong the 3,125 enrolled patients, 506 (16.19%) developed HPR. The influence of HPR on extremely poor prognosis was reflected by recurrence features, adverse effects on systemic and liver function, and limited therapeutic options. Nine variables closely associated with HPR were identified, and incorporated into nomogram and conditional inference tree models, which successfully achieved pre- and post-operative HPR risk stratification and facilitated clinical decision-making. Multi-dimensional verification also confirmed the predictive accuracy of model combinations and their reliability in clinical applications. Furthermore, biological analyses revealed that HCCs with HPR exhibited hyperactive biological processes, inactive metabolism, and immune exhaustion features, together with high MYCN/HMGA2 co-expression, thereby enhancing understanding of the molecular events leading to HPR and providing valuable knowledge for HPR management.

conclusionsHPR after hepatectomy is associated with extremely poor prognosis and requires substantial attention. We constructed comprehensive predictive models and propose a clinical strategy for guiding HPR prevention and management.

Indexed as

Carcinoma, HepatocellularHepatectomyLiver NeoplasmsNeoplasm Recurrence, LocalAdultAgedDisease ProgressionFemaleHumansMaleMiddle AgedNomogramsPrognosisRisk AssessmentRisk Factorsbiological featureclinical strategyHepatocellular carcinomahyper-progression recurrencepredictive models

Identifiers

PMID40643201
PMCPMC12418268

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.